Serum and urinary golgi membrane protein 1 (GOLM1/GP73/G73) for chronic kidney disease staging - Scorecard - MDSpire

Serum and urinary golgi membrane protein 1 (GOLM1/GP73/G73) for chronic kidney disease staging

  • By

  • Jiaqi Xu

  • Jiawen Lin

  • Chao Ma

  • Jianishaya Yeerlan

  • Shuping Li

  • Wenjian Zhu

  • Zhihua Zheng

  • Mingcheng Huang

  • July 10, 2026

  • 0 min

Share

Clinical Scorecard: Evaluation of Serum and Urinary Golgi Membrane Protein 1 (GOLM1/GP73) as Biomarkers for Staging Chronic Kidney Disease

At a Glance

CategoryDetail
ConditionChronic Kidney Disease (CKD)
Key MechanismsSerum G73 levels increase with CKD severity; urinary G73 levels decline, reflecting tubular function.
Target PopulationPatients with CKD stages 1-5 and healthy individuals.
Care SettingDepartment of Nephrology, Center of Kidney and Urology, The Seventh Affiliated Hospital, Sun Yat-Sen University.

Key Highlights

  • Serum G73 levels increase from healthy controls to CKD stages 4-5.
  • Urinary G73 and the urine G73-to-creatinine ratio decline with CKD progression.
  • Adding serum G73 improves discrimination of advanced CKD in clinical models.
  • Serum G73 shows modest ability to distinguish AKI from CKD.
  • Urinary G73 reflects tubular function and may serve as a non-invasive biomarker.

Guideline-Based Recommendations

Diagnosis

  • Evaluate serum and urinary G73 for staging CKD.

Management

  • Consider serum G73 in clinical models for assessing CKD severity.

Monitoring & Follow-up

  • Monitor serum and urinary G73 levels to assess disease progression.

Risks

  • Be aware of the limitations of conventional markers like eGFR and albuminuria.

Patient & Prescribing Data

Patients with chronic kidney disease across various stages.

Serum G73 may provide additional diagnostic value beyond traditional markers.

Clinical Best Practices

  • Incorporate serum G73 measurements in CKD staging protocols.
  • Use urinary G73 levels to assess tubular function in CKD patients.

Related Resources & Content

Original Source(s)

Serum and urinary golgi membrane protein 1 (GOLM1/GP73/G73) for chronic kidney disease staging

  • by Jiaqi Xu, Jiawen Lin, Chao Ma, Jianishaya Yeerlan, Shuping Li, Wenjian Zhu, Zhihua Zheng, Mingcheng Huang

  • July 10, 2026

Related Content

Oral Microbiome Richness Tied to CRS

A cross-sectional metagenomic study found greater oral microbiome richness among adults with chronic rhinosinusitis, particularly nonallergic chronic rhinosinusitis, while associations with asthma, airway inflammation, and most lung-function measures were inconsistent.

Same-Day COVID, Flu Vaccination Appears Safe

Study found no increased 90-day risk of serious adverse events with coadministration compared with vaccination alone.

Can AI Aid Urine Drug Test Sign-Outs?

Researchers reported that an artificial intelligence workflow maintained high interpretive accuracy while reducing urine drug test sign-out time in a supervised clinical laboratory setting.